Takeda said it will discontinue development of TAK‑341 (MEDI1341), an alpha‑synuclein antibody it was co‑developing with AstraZeneca, after a global Phase 2 study in multiple system atrophy (MSA) failed to meet primary or secondary endpoints. The company concluded the data do not support further development in MSA and removed the program from its pipeline. Takeda also disclosed strategic discontinuation of several early‑stage programs, including a gamma‑delta T‑cell candidate and a narcolepsy indication for another candidate, reflecting a broader pipeline reweighting. AstraZeneca still lists TAK‑341 in its Phase 2 pipeline, and the original collaboration covered Parkinson’s disease as well, but Takeda’s move signals a retreat from this modality in its portfolio. The failure underscores the difficulty of translating alpha‑synuclein targeting into clinical benefit and may prompt partners and investors to reassess risk in neurodegenerative antibody programs.